Rothschild & CO Asset Management Us Inc. Esperion Therapeutics, Inc. Transaction History

Rothschild & CO Asset Management Us Inc.

14 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2020 Feb 08, 2021	SELL	$24.2 - $35.76 $9.53 Million - $14.1 Million	-393,839 Closed	0 $0
Q3 2020 Nov 09, 2020	SELL	$31.18 - $52.71 $1.04 Million - $1.76 Million	-33,429 Reduced 7.82%	393,839 $14.6 Million
Q2 2020 Aug 10, 2020	BUY	$30.04 - $51.31 $1.19 Million - $2.04 Million	39,685 Added 10.24%	427,268 $21.9 Million
Q1 2020 May 14, 2020	BUY	$27.44 - $73.84 $2.54 Million - $6.83 Million	92,502 Added 31.35%	387,583 $12.2 Million
Q4 2019 Feb 12, 2020	BUY	$35.4 - $59.82 $9.87 Million - $16.7 Million	278,834 Added 1716.22%	295,081 $17.6 Million
Q3 2019 Nov 08, 2019	SELL	$34.47 - $47.53 $5,136 - $7,081	-149 Reduced 0.91%	16,247 $596,000
Q2 2019 Jul 25, 2019	SELL	$40.1 - $52.33 $8,701 - $11,355	-217 Reduced 1.31%	16,396 $763,000
Q1 2019 May 08, 2019	SELL	$40.11 - $53.57 $421,676 - $563,181	-10,513 Reduced 38.76%	16,613 $667,000
Q4 2018 Feb 05, 2019	SELL	$36.99 - $59.11 $9,432 - $15,073	-255 Reduced 0.93%	27,126 $1.25 Million
Q3 2018 Nov 13, 2018	BUY	$40.74 - $51.41 $148,456 - $187,338	3,644 Added 15.35%	27,381 $1.22 Million
Q2 2018 Aug 07, 2018	BUY	$36.2 - $76.4 $174,411 - $368,095	4,818 Added 25.47%	23,737 $930,000
Q1 2018 May 08, 2018	SELL	$65.94 - $80.76 $128,714 - $157,643	-1,952 Reduced 9.35%	18,919 $1.37 Million
Q4 2017 Feb 12, 2018	SELL	$43.47 - $67.43 $67,552 - $104,786	-1,554 Reduced 6.93%	20,871 $1.37 Million
Q3 2017 Nov 08, 2017	BUY	$43.8 - $52.77 $982,214 - $1.18 Million	22,425	22,425 $1.12 Million

199

136M

2.72M

1.3M

Ticker ESPR
Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—Specialty & Generic
Shares Outstandng 66,551,600
Market Cap $112M
Description
Esperion Therapeutics, Inc., a pharmaceutical company, develops and commercializes medicines for the treatment of patients with elevated low density lipoprotein cholesterol. Its lead product candidates are NEXLETOL (bempedoic acid) and NEXLIZET (bempedoic acid and ezetimibe) tablets for the treatment of patients with atherosclerotic cardiovascul...

Get notified when there are updates to the investment portfolio of Rothschild & CO Asset Management Us Inc., based on Form 13F filings with the SEC.

Stay updated on Rothschild & CO Asset Management Us Inc. with notifications on news.